FDA clears IND for CLN-978 for the Treatment of Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
“Despite advances for the treatment of B-cell malignancies, substantial unmet need remains for effective treatments. Preclinical evidence has demonstrated a differentiated profile for CLN-978 as it binds with very high affinity to CD19-expressing cells even at barely detectable levels of CD19.” said Jeffrey Jones, MD, MPH, MBA, Chief Medical Officer, Cullinan Oncology. “Consistent with our mission to create new standards of care for patients with cancer, CLN-978 has the potential to become a best-in-class treatment option for patients with B-cell malignancies by offering a highly potent off-the-shelf treatment that is delivered subcutaneously, resulting in more patient-friendly administration and potentially reduced toxicity. We are proud to advance this program, which came through our internal discovery pipeline and is Cullinan Oncology’s fourth clinical-stage asset, and we will be working diligently with investigators to enroll patients in our study.”
Share:
More News
“Cancer, a leading cause of death worldwide, exacts an immense toll on individuals, families, and communities. No person, family, scientist, clinician, hospital, policy maker, company or country can or should face this devastating disease alone. We all must work together to win, which is why we are committed to playing
“Our encouraging Phase 2 data for GRANITE in MSS-CRC continue to mature and demonstrate durable benefit over time. With two additional months of follow-up, relative progression-free survival has further improved in the analysis of all patients treated with GRANITE, and most notably, in those with a lower tumor burden at
“Patients in the EU with ROS1 -positive non-small cell lung cancer and NTRK -positive solid tumors face a great unmet need for new therapies that may improve their outcomes and address or delay the difficult issue of treatment resistance,” said Joseph Fiore, vice president, global program lead, repotrectinib, Bristol Myers
“The acquisition of Biotheus builds on our successful ongoing collaboration on BNT327/PM8002 and other investigational bispecific antibodies,” said Prof. Ugur Sahin, M.D., Ph.D., CEO and co-founder of BioNTech. “We believe that BNT327/PM8002 has the potential to set a new standard of care in multiple oncology indications, surpassing traditional checkpoint inhibitors.
